Antibacterial drugs are derived from bacteria or molds or are synthesized de novo and can be classified in several ways – bacteriostatic or bacteriocidal, by chemical structure, according to their mode of action, or according to their spectrum of activity. Antibiotics have many mechanisms of action, including inhibiting cell wall synthesis, increasing cell membrane permeability, and interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes (e.g. folic acid synthesis). The antibacterial agents possess bactericidal activity which target various parts of bacterial physiology, such as protein synthesis, cell wall synthesis, nucleic acid synthesis and permeability of cell membrane, and therefore help in treating infections.
The antibacterial drugs market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug classes (aminoglycosides; β-lactams including penicillins, carbapenems, cephalosporin; macrolides; phenicols; quinolones/fluoroquinolone; sulfonamides; and tetracyclines) and clinical pipeline analysis of phase 1,2 and 3 drugs, and forecasts growth trends (CAGR% – 2017 to 2021).
The global antibacterial drugs market segmentation is based on geography (regional and country based). The global antibacterial drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products,
technologies and services offered, and recent developments. The global antibacterial drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Some of the major players profiled in this report include AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly & Co., Allergan plc, GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Merck & Co., Inc., and others.